Literature DB >> 12057073

Recurrent cervical cancer.

Mario M Leitao1, Dennis S Chi.   

Abstract

There are limited treatment options for patients with recurrent cervical carcinoma. Because of low response rates and a negligible impact on long-term survival, the use of chemotherapy in patients with unresectable recurrent disease should be considered palliative. Generally, radiation therapy in previously irradiated patients is considered palliative. For patients who develop recurrent disease after definitive surgery who have not received prior radiation therapy, salvage radiation therapy is the treatment of choice. Similarly, patients who have received definitive primary radiation therapy are candidates for surgical resection of their recurrence. However, there are specific criteria for surgical resection. Radical hysterectomy may be an option for the very rare patient with a small (<2 cm) centrally located recurrence in the cervix or vaginal fornices. However, for most patients, pelvic exenteration remains the only therapeutic option that offers the possibility of long-term survival. Patients who are candidates for exenteration are those with central local recurrences that have not extended to the pelvic sidewalls. The introduction of high-dose-rate intraoperative radiation therapy (HDR-IORT) combined with radical surgical resection has widened the scope of patients who may be offered surgery. Patients who in the past may not have been surgical candidates may benefit from radical surgical resection combined with HDR-IORT. All patients who are surgically fit and have undergone previous radiation therapy should be considered for surgical resection for centrally located recurrences. Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available.

Entities:  

Mesh:

Year:  2002        PMID: 12057073     DOI: 10.1007/s11864-002-0056-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  14 in total

Review 1.  Radical abdominal hysterectomy.

Authors:  N R Abu-Rustum; W J Hoskins
Journal:  Surg Clin North Am       Date:  2001-08       Impact factor: 2.741

Review 2.  Chemotherapy of advanced and recurrent cervical carcinoma.

Authors:  H N Nguyen; S R Nordqvist
Journal:  Semin Surg Oncol       Date:  1999 Apr-May

Review 3.  Surgical management of advanced and recurrent cervical cancer.

Authors:  R Estape; R Angioli
Journal:  Semin Surg Oncol       Date:  1999 Apr-May

Review 4.  The role of intraoperative radiation therapy (IORT) in the treatment of locally advanced gynecologic malignancies.

Authors:  M G del Carmen; J F McIntyre; A Goodman
Journal:  Oncologist       Date:  2000

5.  Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy.

Authors:  A BRUNSCHWIG
Journal:  Cancer       Date:  1948-07       Impact factor: 6.860

Review 6.  Long-term experience in the surgical management of cancer of the uterine cervix.

Authors:  D S Chi; M L Gemignani; J P Curtin; W J Hoskins
Journal:  Semin Surg Oncol       Date:  1999 Oct-Nov

7.  Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers.

Authors:  M L Gemignani; K M Alektiar; M Leitao; B Mychalczak; D Chi; E Venkatraman; R R Barakat; J P Curtin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

Review 8.  Cervical cancer.

Authors: 
Journal:  NIH Consens Statement       Date:  1996 Apr 1-3

9.  Radical hysterectomy for recurrent cervical cancer following radiation therapy.

Authors:  S C Rubin; W J Hoskins; J L Lewis
Journal:  Gynecol Oncol       Date:  1987-07       Impact factor: 5.482

10.  Clinical experiences with intraoperative radiotherapy of locally advanced cancers.

Authors:  M Abe; M Takahashi; E Yabumoto; H Adachi; M Yoshii; K Mori
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

View more
  13 in total

1.  Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs).

Authors:  Xingzhu Ju; Shanhui Liang; Jun Zhu; Guihao Ke; Hao Wen; Xiaohua Wu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.

Authors:  M A Terán-Porcayo; I Zeichner-Gancz; R A C Gomez del-Castillo; A Beltrán-Ortega; G Solorza-Luna
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines.

Authors:  Jin-Ling Yi; Song Shi; Yan-Li Shen; Ling Wang; Hai-Yan Chen; Jun Zhu; Yan Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation.

Authors:  Amit K Garg; Anuja Jhingran; Ann H Klopp; Bharat B Aggarwal; Ajai B Kunnumakkara; Russell R Broadus; Patricia J Eifel; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

5.  c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.

Authors:  Tamer Refaat; Eric D Donnelly; Sean Sachdev; Vamsi Parimi; Samar El Achy; Prarthana Dalal; Mohamed Farouk; Natasha Berg; Irene Helenowski; Jeffrey P Gross; John Lurain; Jonathan B Strauss; Gayle Woloschak; Jian-Jun Wei; William Small
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

6.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 7.  Updates in systemic treatment for metastatic cervical cancer.

Authors:  Angel Chao; Cheng-Tao Lin; Chyong-Huey Lai
Journal:  Curr Treat Options Oncol       Date:  2014-03

8.  Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.

Authors:  Carlos Lopez-Graniel; Rigoberto Dolores; Lucely Cetina; Aaron Gonzalez; David Cantu; Jose Chanona; Jesus Uribe; Myrna Candelaria; Rocio Brom; Jaime de la Garza; Alfonso Duenas-Gonzalez
Journal:  BMC Cancer       Date:  2005-09-19       Impact factor: 4.430

9.  Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.

Authors:  Etienne Muller; Baptiste Brault; Allyson Holmes; Angelina Legros; Emmanuelle Jeannot; Maura Campitelli; Antoine Rousselin; Nicolas Goardon; Thierry Frébourg; Sophie Krieger; Hubert Crouet; Alain Nicolas; Xavier Sastre; Dominique Vaur; Laurent Castéra
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

10.  Stretching the Limits of Laparoscopy in Gynecological Oncology: Technical Feasibility of doing a Laparoscopic Total Pelvic Exenteration for Palliation in advanced Cervical Cancer.

Authors:  S P Puntambekar; G A Agarwal; S S Puntambekar; R M Sathe; A M Patil
Journal:  Int J Biomed Sci       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.